|Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients|
A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ...
Nature medicine 23 (6), 703, 2017
|Tumor mutational load predicts survival after immunotherapy across multiple cancer types|
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
|Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for …|
DT Cheng, TN Mitchell, A Zehir, RH Shah, R Benayed, A Syed, ...
The Journal of molecular diagnostics 17 (3), 251-264, 2015
|Inherited DNA-repair gene mutations in men with metastatic prostate cancer|
CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, ...
N Engl J Med 375, 443-453, 2016
|OncoKB: a precision oncology knowledge base|
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
|Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled …|
H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ...
Journal of Clinical Oncology 36 (7), 633, 2018
|Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy|
D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ...
Science 359 (6375), 582-587, 2018
|AACR Project GENIE: powering precision medicine through an international consortium|
AACR Project Genie Consortium
Cancer discovery 7 (8), 818-831, 2017
|Variant review with the integrative genomics viewer|
JT Robinson, H Thorvaldsdóttir, AM Wenger, A Zehir, JP Mesirov
Cancer research 77 (21), e31-e34, 2017
|Clinical sequencing defines the genomic landscape of metastatic colorectal cancer|
R Yaeger, WK Chatila, MD Lipsyc, JF Hechtman, A Cercek, ...
Cancer cell 33 (1), 125-136. e3, 2018
|Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes|
CC Coombs, A Zehir, SM Devlin, A Kishtagari, A Syed, P Jonsson, ...
Cell stem cell 21 (3), 374-382. e4, 2017
|The genomic landscape of endocrine-resistant advanced breast cancers|
P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ...
Cancer cell 34 (3), 427-438. e6, 2018
|Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies|
EJ Jordan, HR Kim, ME Arcila, D Barron, D Chakravarty, JJ Gao, ...
Cancer discovery 7 (6), 596-609, 2017
|Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing|
D Mandelker, L Zhang, Y Kemel, ZK Stadler, V Joseph, A Zehir, ...
Jama 318 (9), 825-835, 2017
|Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions|
JF Hechtman, R Benayed, DM Hyman, A Drilon, A Zehir, D Frosina, ...
The American journal of surgical pathology 41 (11), 1547, 2017
|Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade|
W Abida, ML Cheng, J Armenia, S Middha, KA Autio, HA Vargas, ...
JAMA oncology 5 (4), 471-478, 2019
|Germline variants in targeted tumor sequencing using matched normal DNA|
KA Schrader, DT Cheng, V Joseph, M Prasad, M Walsh, A Zehir, A Ni, ...
JAMA oncology 2 (1), 104-111, 2016
|Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response|
R Mandal, RM Samstein, KW Lee, JJ Havel, H Wang, C Krishna, ...
Science 364 (6439), 485-491, 2019
|Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making|
W Abida, J Armenia, A Gopalan, R Brennan, M Walsh, D Barron, D Danila, ...
JCO precision oncology 1, 1-16, 2017
|Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer|
A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, ...
Journal of Clinical Oncology 37 (4), 286, 2019